Baird Reiterates Buy Rating on Nurix Therapeutics, Inc.
Baird maintains its Buy rating with a $33 price target for Nurix Therapeutics, a 76.23% upside from the current price.
Key Points
- Baird reiterated its Buy rating on Nurix Therapeutics, Inc. (NRIX) with a $33 price target on June 18, 2026.
- Baird's $33 price target implies 76.23% upside from Nurix Therapeutics, Inc.'s ($NRIX) current $18.73 share price.
- Nurix Therapeutics trades at $17.56 on NasdaqGM, with a market cap of $1.77 billion and a beta of 1.869.
- BlackRock and State Street have been active in NRIX, with State Street increasing its holdings by 1,581,694 shares.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 18, 2026, Baird reiterated its Buy rating on Nurix Therapeutics, Inc. (NasdaqGM: NRIX) with a price target of $33. This comes as the stock trades at $17.56.
Other Institutional Activity in Nurix Therapeutics
Several institutional investors have made changes to their holdings in Nurix Therapeutics. BlackRock, Inc. increased its position by 50,448 shares, bringing its total to 8,925,642 shares valued at approximately $138.3 million. Meanwhile, State Street Corp significantly boosted its stake by 1,581,694 shares, now holding 5,141,195 shares worth about $79.7 million. On the other hand, Redmile Group, LLC trimmed its position by 361,100 shares, ending with 7,732,808 shares valued at $119.9 million.
Nurix Therapeutics, Inc. Stock Down 28.6%
Shares of Nurix Therapeutics, Inc. (NasdaqGM: NRIX) are trading near $17.56. The company has a market cap of approximately $1.77 billion and a beta of 1.869, suggesting higher volatility compared to the broader market. The stock's 52-week range is between $8.20 and $22.50, with a 50-day moving average of $16.50 and a 200-day moving average of $15.04.
Recent Earnings
Nurix Therapeutics reported revenue of $71.78 million, though it experienced a revenue decline of 66.1%. The company is not yet profitable, with a negative return on equity of 61.4%. The next earnings date is scheduled for July 9, 2026.
Insider Buying and Selling at Nurix Therapeutics, Inc.
Recent insider activity at Nurix Therapeutics includes transactions by Chief Legal Officer Christine Ring. On June 2, 2026, she sold 3,422 shares and purchased the same amount at an average price of $1.86. Additionally, on the same day, she sold 8,148 shares at $16.60 under a planned sale. Other insiders, including Roy Baynes and Paul Silva, each bought 31,250 shares on May 15, 2026.
Analysts Set New Price Targets
On June 18, 2026, Baird maintained its Buy rating for Nurix Therapeutics with a $33 price target. Needham also reiterated a Buy rating with a $34 target on June 15, 2026. Truist Securities and BTIG both maintained Buy ratings with $32 targets on June 9, 2026. The consensus among 16 analysts is a strong buy, with an average target price of $31.
About Nurix Therapeutics
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California. Led by CEO Dr. Arthur T. Sands, the company focuses on developing therapies for cancer and inflammatory diseases. Its pipeline includes several promising candidates, such as NX-5948 for B-cell malignancies and NX-1607 for immuno-oncology indications. With strategic collaborations with major pharmaceutical companies like Gilead, Sanofi, and Pfizer, Nurix is at the forefront of innovative drug development.
Bottom Line
Baird's reaffirmation of its Buy rating on Nurix Therapeutics highlights continued confidence in the company's potential. With a robust pipeline and strategic partnerships, Nurix remains a company to watch in the biotech sector. Investors should note that analyst ratings like this are based on past and current assessments and may not reflect future performance.
Get Nurix Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NRIX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.